The third-generation TKI, bosutinib, has displayed limited therapeutic potential for treating CML patients expressing somatic mutations found within the BCR-ABL kinase domain, specifically the T315I mutation [6]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.